Therapeutic Hypothermia for Neonatal Hypoxic-Ischemic Encephalopathy in Vietnam

NCT07555652 — Not applicable, Recruiting, 120 participants, National Children's Hospital, Vietnam

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Efficacy of Controlled Therapeutic Hypothermia for Neonatal Hypoxic-Ischemic Encephalopathy (HIE)

RegistryNCT07555652, acronym HIE-TH Vietnam
StatusRecruiting
PhaseNot applicable
Study typeInterventional; na, single group, masking: none, treatment
Enrollment120 (Estimated)
SponsorNational Children's Hospital, Vietnam (Other)
ConditionsHypoxic-ischemic Encephalopathy (HIE)
InterventionsTherapeutic Hypothermia (Procedure)
Datesstart 2025-06-10, primary completion 2027-05-01 (estimated), completion 2028-02-01 (estimated), first posted 2026-04-29, last updated 2026-04-29
Locations1 site in Vietnam

Related Papers Related Patents Related Grants Related Experts
All trials for Hypoxic-ischemic Encephalopathy (HIE) All trials of Therapeutic Hypothermia

-Summary

This study aims to evaluate the effectiveness of therapeutic hypothermia in neonates diagnosed with hypoxic-ischemic encephalopathy (HIE). The study focuses on assessing both short-term outcomes after treatment and long-term neurological outcomes following therapeutic hypothermia.

Expand all sections  ·  Collapse all

+Detailed description

Hypoxic-ischemic encephalopathy (HIE) is a major cause of neonatal mortality and long-term neurological impairment, resulting from perinatal hypoxia-ischemia. Therapeutic hypothermia is currently considered a key treatment modality for reducing brain injury and improving outcomes in affected neonates.

This study is designed to:

Develop and standardize technical procedures and indications for therapeutic hypothermia in neonates with HIE Evaluate short-term treatment outcomes following therapeutic hypothermia Assess long-term neurological outcomes after treatment Identify factors associated with treatment outcomes in neonates with HIE

The study will be conducted at the National Children's Hospital, Vietnam, over the period from 2025 to 2028

+Arms and interventions

ArmTypeInterventionsDescription
Therapeutic HypothermiaExperimentalProcedure: Therapeutic HypothermiaNeonates diagnosed with hypoxic-ischemic encephalopathy (HIE) who meet the protocol-defined eligibility criteria will receive therapeutic hypothermia. Eligible infants are those born at or after 36 weeks of gestation, younger than 6 hours of age, and meeting the required clinical and biochemical criteria for therapeutic hypothermia according to the study protocol.
  • Therapeutic Hypothermia (Procedure): Therapeutic hypothermia will be administered to neonates with HIE according to the protocolized technical procedure developed and standardized in the study. The intervention is initiated in eligible neonates within 6 hours after birth and is performed with continuous clinical and neurologic monitoring as specified in the protocol.

+Outcome measures

Primary outcomes

  • Survival to hospital discharge [At hospital discharge (up to 28 days of life)]: Proportion of neonates with hypoxic-ischemic encephalopathy (HIE) who survive to hospital discharge following therapeutic hypothermia.

Secondary outcomes

  • Neurodevelopmental outcome assessed by Bayley Scales of Infant Development III (BSID-III) [At 24 months of age]: Cognitive, language, and motor composite scores assessed using BSID-III in infants treated with therapeutic hypothermia for HIE.
  • Correlation between Sarnat stage at baseline and neurodevelopmental outcome [From baseline to 24 months of age]: Correlation between baseline Sarnat stage (ordinal scale) and BSID-III cognitive composite score at 24 months.

+Eligibility

Sex: All, ages: 0 Hours to 6 Hours

Inclusion Criteria:

* Neonates diagnosed with hypoxic-ischemic encephalopathy (HIE) at the Neonatal Center, National Children's Hospital
* Gestational age ≥ 36 weeks
* Assessed using the modified Sarnat staging within the first 0-6 hours after birth
* Eligible for and/or treated with therapeutic hypothermia according to institutional protocol
* Underwent clinical and paraclinical monitoring during hospitalization
* Received brain magnetic resonance imaging (MRI) during the neonatal period (from 5 to 17 days of age)
* Availability of complete medical records for data collection and analysis

Exclusion Criteria:

* Presence of major congenital anomalies, particularly involving the central nervous system
* Absence of brain MRI during the study period
* Refusal of participation by parent(s) or legal guardian(s)

+Locations (1)

FacilityCityCountryStatus
Vietnam National Children's HospitalvHa Nội, HanoiVietnamRecruiting